Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.

Given that a typical patient with a high bodyweight (e.g., upper 97.5th percentile) showed a trend for higher exposures by bodyweight-based dosing in the sensitivity analysis, which could potentially be associated with safety concerns, the exposures for the subgroup of heavy patients were compared with the rest of the patients using pCC-based simulation.

also in 53,322 other papers